An observational study in Liver Diseases, Liver Dysfunction and Liver Transplant Disorder, sponsored by Paragonix Technologies. Enrolling by invitation at 15 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Paragonix Technologies · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Liver Diseases with a site in United States — 46 open to participants now, 60 under way, 5 of them phase 3. Liver Diseases · United States.
Among the 369 studies in Liver Diseases with a site in United States, this one is the 8th largest by planned enrollment of the 90 observational ones that give a count, is one of 25 that started in 2022, is one of 91 observational ones, reaches primary completion later than 18 of the 58 other live ones, and was the 284th registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →46 of the 369 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States
Ages 18–80
West Virginia University · Sites in United States
Ages 18+
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
Incyte Corporation · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 72 · Phase 2 75 · Phase 3 30 · Phase 4 21
First in 1988; this study’s year is marked. 25 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 200 across 262 observational studies indexed under Liver Diseases.
Median enrollment 48 across the 270 interventional studies, 153 across the 90 observational. Of the 276 that completed or were terminated, 115 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 369 have an industry lead sponsor. The 10 most frequent:
Paragonix Technologies is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Paragonix Technologies has 1 study filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
22 of the studies in Liver Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT05264051University of ChicagoMAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | 2027-03-01 |
| NCT07746999Corey DeStefanoNorth Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health | 2027-03-15 |
Add all 22 to your calendar (.ics) → With an account.
Among the 369 studies in Liver Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor liver that were preserved and transported within the LIVERguard system, as well as retrospective standard of care patients
GUARDIAN-Liver is a post-market, observational registry of adult and pediatric liver transplant recipient patients whose donor liver was preserved and transported within the LIVERguard. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 2,000 male and female subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 20 clinical sites.
Candidates that fit the eligibility criteria and have had their donor liver transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.
Patients who have received a liver transplant at centers that use the LIVERguard device
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients whose donor liver was transported with the LiverGuard device.
Device: LIVERguard
Patients whose donor liver was transported with a method other than the LiverGuard
The LIVERguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of livers during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the liver. The intended organ storage time for the LIVERguard is up to 16 hours.
Graft Failure
The percentage of subjects in each cohort who develop graft failure post-transplant
Time frame: Post-transplant through 1 year post
Early allograft dysfunction
The percentage of subjects in each cohort who early allograft failure post-transplant
Time frame: 7 days post transplant
Rejection
The percentage of subjects in each cohort who experience rejection post-transplant
Time frame: Post-transplant through 1 year post
Primary Non-function
The percentage of subjects in each cohort who experience primary non-function post-transplant
Time frame: Post transplant to 7 days post-transplant
Survival
The percentage of subjects in each cohort who survive through 1 year post-transplant
Time frame: Transplant through 1 year post-transplant
Length of Stay
How many days the patient stays in the hospital post-transplant
Time frame: 1 year
Length of ICU stay
How many days the patient stayed in the ICU post-transplant
Time frame: 1 year
Hospitalizations
Amount of times patient is rehospitalized after discharge post-transplant
Time frame: post-transplant through 1 year
Biliary complications
Percentage of patients that experience biliary strictures in each cohort as determined by lab work
Time frame: post-transplant through 1 year post-transplant
Started Mar 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Paragonix Technologies